Arvinas, Inc (ARVN) Dividend History

Company News

• Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

  Arvinas has submitted a New Drug Application to the FDA for vepdegestrant, a potential treatment for patients with ESR1-mutated ER+/HER2- advanced or metastatic breast cancer. The submission is based on positive results from the VERITAC-2 Phase 3 clinical trial.

  GlobeNewswire Inc.

  Featured Companies: PFE
• Kirby McInerney LLP Announces Investigation of Claims Against FTI Consulting, Inc. (FCN) on Behalf of Investors

  Kirby McInerney LLP is investigating potential claims against FTI Consulting, Inc. (FCN) due to a decline in revenue and net income, as well as a special charge related to severance and other employee-related costs.

  GlobeNewswire Inc.

  Featured Companies: FCN LPRO
• Metastatic HR+/HER2- Breast Cancer Market—The Road Ahead for Targeted Therapies and Personalized Medicine | DelveInsight

  The metastatic HR+/HER2- breast cancer market is expected to grow due to the launch of several novel emerging therapies, which are anticipated to change the treatment landscape and improve survival outcomes for this patient population.

  GlobeNewswire Inc.

  Featured Companies: LLY OLMA PFE
• Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

  Arvinas presented positive first-in-human data for its investigational oral PROTAC ARV-102, which demonstrated blood-brain barrier penetration and substantial LRRK2 degradation in both central and peripheral tissues. These findings support the continued evaluation of ARV-102 in neurodegenerative diseases associated with LRRK2 dysfunction.

  GlobeNewswire Inc.
• Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases

  Arvinas, a clinical-stage biotechnology company, announced that data from a first-in-human study of its investigational PROTAC LRRK2 degrader, ARV-102, will be presented at the International Conference on Alzheimer's and Parkinson's Diseases in 2025.

  GlobeNewswire Inc.